Close Menu
PNN DigitalPNN Digital
    Facebook X (Twitter) Instagram
    PNN DigitalPNN Digital
    • Business
    • National
    • Entertainment
    • Lifestyle
    • Education
    • Press Release
    • Submit Your PR
    PNN DigitalPNN Digital
    Home - Health - RAAINBOW Phase 2/3 Paediatric Alopecia Areata Trial Featuring CliniExperts Research Services Published in British Journal of Dermatology
    Health

    RAAINBOW Phase 2/3 Paediatric Alopecia Areata Trial Featuring CliniExperts Research Services Published in British Journal of Dermatology

    PNN Online DeskBy PNN Online DeskSeptember 11, 2025No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    CliniExperts Research Services
    Share
    Facebook Twitter LinkedIn Pinterest Email

    New Delhi [India], September 11:  CliniExperts Research Services is proud to announce its contribution to the RAAINBOW Phase 2/3 global clinical trial, evaluating Cinainu, the world’s first botanical topical drug candidate for the treatment of moderate to severe paediatric Alopecia Areata (AA). The groundbreaking results have been published in the British Journal of Dermatology on 16th of July, 2025. 

    CliniExperts Research Services played a key role in conducting the India arm of the trial, managing clinical operations across multiple sites, data analysis, and reporting, in collaboration with Legacy Healthcare, the Switzerland-based biopharmaceutical company leading the trial.

    About Paediatric Alopecia Areata & Cinainu

    Alopecia Areata (AA) is an autoimmune disorder causing patchy hair loss, with limited safe treatment options for children. Cinainu is a patented botanical topical solution targeting inflammation, apoptosis, and oxidative stress in AA physiology.

    About the RAAINBOW Trial

    ●multinational, randomized, double-blind, placebo-controlled, multicentric Phase 2/3 trial in paediatric AA.

    ●Conducted across 12 sites in 4 countries with 107 patients aged 2–18 years

    ●India’s contribution: Led by CliniExperts Research Services, which ensured compliance with safety, regulatory, and quality standards while delivering comprehensive data analysis.

    ●Results of the trial are available on the BJD website 

    Leadership Voices

    Saad Harti, Founder & CEO, Legacy Healthcare, said, “Beyond its efficacy in regrowing patients’ scalp hair, Cinainu has been shown to treat this autoimmune disease without immunosuppression-related adverse events, and with persistent efficacy, which, to our knowledge, is a first. Publication in the British Journal of Dermatology marks a key milestone supporting Cinainu’s efficacy and safety.”

    CliniExperts Research Services stated, “We are honoured to have contributed to the successful execution of the Indian arm of this global trial. Our role in ensuring quality conduct and delivering country-specific trial design demonstrates CliniExperts’ growing leadership in global dermatology research.”

    About Legacy Healthcare

    Legacy Healthcare is a Switzerland-based biopharmaceutical company pioneering safe, plant-based therapeutics for chronic diseases.

    About CliniExperts Research Services

    CliniExperts Research Services is a leading clinical research organization based in India, specializing in high-quality clinical operations, regulatory expertise, and data analysis across multiple therapeutic areas. Its strong commitment to innovation and compliance enables global biopharmaceutical partners to achieve breakthrough outcomes.

    To know more details, please visit: CliniExperts Research  Services 

    If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.

    aediatric Alopecia Areata Trial British Journal CliniExperts dermatology Phase 2/3 RAAINBOW Research Services
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    PNN Online Desk
    • Website

    Related Posts

    Unihealth Hospitals Limited Celebrates Milestone: First IVF Twins Born at UMC Victoria Hospital in Uganda

    February 23, 2026

    SEPC Limited Order Book Scales New Peak; Rs 10,455 Crore

    February 23, 2026

    Sunrise Capital Brings Its Design-First Philosophy to Dubai Hills and Wasl Gate

    February 23, 2026
    Add A Comment

    Comments are closed.

    Recent Posts
    • Unihealth Hospitals Limited Celebrates Milestone: First IVF Twins Born at UMC Victoria Hospital in Uganda
    • SEPC Limited Order Book Scales New Peak; Rs 10,455 Crore
    • Sunrise Capital Brings Its Design-First Philosophy to Dubai Hills and Wasl Gate
    • KRAFTON Appoints Kangwook Lee as Chief AI Officer
    • Growing Demand for SMM Panels Reflects Changing Social Media Strategy in 2026

    Unihealth Hospitals Limited Celebrates Milestone: First IVF Twins Born at UMC Victoria Hospital in Uganda

    February 23, 2026

    SEPC Limited Order Book Scales New Peak; Rs 10,455 Crore

    February 23, 2026

    Sunrise Capital Brings Its Design-First Philosophy to Dubai Hills and Wasl Gate

    February 23, 2026

    KRAFTON Appoints Kangwook Lee as Chief AI Officer

    February 23, 2026

    Growing Demand for SMM Panels Reflects Changing Social Media Strategy in 2026

    February 23, 2026

    DES PU’s Unique Programmes and Student-Centric Learning Approach is Empowering Creativity and Careers

    February 23, 2026
    PNN Digital
    2026 © pnn.digital

    Type above and press Enter to search. Press Esc to cancel.